Navigation Links
Alexza Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:11/21/2013

MOUNTAIN VIEW, Calif., Nov. 21, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Company will participate in the 25th Annual Piper Jaffray Healthcare Conference, being held in New York, NY, on December 3 - 4, 2013.  Thomas B. King, Alexza President and CEO, will present at the conference.  The Alexza corporate presentation will be Tuesday, December 3, 2013 at 2:30 p.m. Eastern Time.  The presentation will be webcast live.

To access the presentation via the Web, please go to the Alexza Investor Relations tab at www.alexza.com or at http://www.media-server.com/m/p/ojwv3h6t.  A replay of the webcast will be available approximately 24 hours after the presentation and archived for 30 days.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's products are based on the Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.

ADASUVE (Staccato loxapine) is Alexza's first commercial product, which was approved by the U.S. Food and Drug Administration in December 2012 and by the European Commission in February 2013.  Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for ADASUVE in the U.S.  Grupo Ferrer Internacional, S.A. is Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.  For more information about ADASUVE, please visit www.adasuve.com

ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the ability of Alexza and our partners, Teva and Ferrer, to effectively and profitably commercialize ADASUVE, estimated product revenues and royalties associated with the sale of ADASUVE, the adequacy of the Company's capital to support the Company's operations, and the Company's ability to raise additional funds and the potential terms of such potential financings. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
2. Alexza Receives Complete Response Letter for Adasuve™ NDA
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
4. Alexza Announces Reverse Stock Split in Order to Maintain NASDAQ Listing
5. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
6. Alexza Announces Management Promotions
7. Alexza Reports 2012 Second Quarter Financial Results and Provides Business Update
8. Alexza Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
9. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
10. Alexza to Report 2012 Year-End Financial Results on Tuesday, March 26, 2013
11. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017  Sensus Healthcare, Inc. ... company specializing in the treatment of non-melanoma skin ... with superficial radiation therapy, today announced that it ... 2016 financial results on Thursday, February 2, 2017 after ... hold a conference call with the investment community ...
(Date:1/19/2017)... England , January 19, 2017 ... and Otsuka in the Milner Therapeutics Consortium   ... scientists in Cambridge   ... (NYSE: PFE ) as a partner to ... the Consortium, which enables the efficient transfer of materials ...
(Date:1/19/2017)... 18, 2017 , , Marks E-QURE ... distribution agreement, following similar agreements in Israel ... care is $2 5 billion global ... Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced ... Equipos Médicos S.A.S. (TeckMedica) in Colombia for the Company,s ...
Breaking Medicine Technology:
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... Source ... botanicals and 100 percent pure essential oils, announced the company had a successful visit ... , The annual ECRM event gives companies that work in the nutritional, sports and ...
(Date:1/20/2017)... ... 20, 2017 , ... International Protein, a company based out of Australia that ... the January ECRM trade show in Hilton Head, SC. , International Protein was ... create a line of products that would elevate her fitness regime. At this ECRM ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a ... has set out for each of his children. “The Angel” is the creation of ... Music in New York City, and impassioned writer. , When asked of her new ...
(Date:1/20/2017)... ... ... “Journey to Christmas:” a beautiful and enchanting tale that teaches children the true meaning of ... three in Oklahoma City, and a devoted woman of faith. , “Becoming a parent ... the back of my mind for years, but actually doing it might have been a ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... E-learning system for Clinical and Regulatory education for Physicians, Physician Advisors, Case ... successful education methodology of Disease Specific Documentation Improvement. , The Aerolib Learning ...
Breaking Medicine News(10 mins):